Kidney Transplantation Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
SKU ID : TNV-14620402 | Publishing Date : 28-Aug-2019 | No. of pages : 129
Detailed TOC of Kidney Transplantation Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Selective cytokine inhibitors - Market size and forecast 2018-2023
• Immunosuppressive antimetabolites - Market size and forecast 2018-2023
• Other drugs - Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Novel techniques for kidney transplantation
• Reimbursement policies for kidney transplantation
• Increasing strategic alliances
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma, Inc.
• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Novartis AG
• Veloxis Pharmaceuticals A/S
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Selective cytokine inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Selective cytokine inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 22: Immunosuppressive antimetabolites - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Immunosuppressive antimetabolites - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Astellas Pharma Inc. - Vendor overview
Exhibit 51: Astellas Pharma Inc. - Business segments
Exhibit 52: Astellas Pharma Inc. - Organizational developments
Exhibit 53: Astellas Pharma Inc. - Geographic focus
Exhibit 54: Astellas Pharma Inc. - Key offerings
Exhibit 55: Astellas Pharma Inc. - Key customers
Exhibit 56: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 58: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 59: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 61: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 62: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 63: Mylan NV - Vendor overview
Exhibit 64: Mylan NV - Product segments
Exhibit 65: Mylan NV - Organizational developments
Exhibit 66: Mylan NV - Geographic focus
Exhibit 67: Mylan NV - Segment focus
Exhibit 68: Mylan NV - Key offerings
Exhibit 69: Mylan NV - Key customers
Exhibit 70: Novartis AG - Vendor overview
Exhibit 71: Novartis AG - Business segments
Exhibit 72: Novartis AG - Organizational developments
Exhibit 73: Novartis AG - Geographic focus
Exhibit 74: Novartis AG - Segment focus
Exhibit 75: Novartis AG - Key offerings
Exhibit 76: Novartis AG - Key customers
Exhibit 77: Veloxis Pharmaceuticals A/S - Vendor overview
Exhibit 78: Veloxis Pharmaceuticals A/S - Business segments
Exhibit 79: Veloxis Pharmaceuticals A/S - Organizational developments
Exhibit 80: Veloxis Pharmaceuticals A/S - Geographic focus
Exhibit 81: Veloxis Pharmaceuticals A/S - Key offerings
Exhibit 82: Veloxis Pharmaceuticals A/S - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors